Clinical trial
Imatinib Mesylate in Treating Patients With Recurrent Meningioma
NCT00045734 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00045734 |
|---|---|
| Title | Imatinib Mesylate in Treating Patients With Recurrent Meningioma |
| Official title | Phase II Trial of STI571 (NSC 716051) in Patients With Recurrent Meningioma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adult Grade I Meningioma, Adult Grade II Meningioma, Adult Grade III Meningioma, Adult Meningeal Hemangiopericytoma, Adult Meningioma, Recurrent Adult Brain Tumor |
| Intervention type | Drug, Other |
| Interventions | imatinib mesylate, laboratory biomarker analysis, pharmacological study |
| Enrollment | 23 |
| Start date | Feb 1, 2003 |
| Primary completion | Dec 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Jan 27, 2003 |
| Last update posted | May 15, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: